Kunovac Kallak, T. 2015. Hormonal Regulation of Vaginal Mucosa. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1076. 65 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9181-9. Vaginal atrophy symptoms such as dryness, irritation, and itching, are common after menopause. Vaginal estrogen therapy is the most effective treatment but not appropria...

Continuous combined hormone therapy (HT) is effective for menopausal vasomotor symptoms and vaginal dryness but commonly leads to unscheduled vaginal bleeding and spotting. Unscheduled bleeding is disliked by women and may lead to invasive investigations to exclude underlying pelvic pathology. In most cases investigations do not reveal any underlying cause for the bleeding.

BACKGROUND There is significant variability of the age at which children achieve dryness. OBJECTIVES We determine the age at achievement of micturational dryness and attitude of parents about enuresis among urban Nigerian children. METHOD A total of 346 questionnaires were administered to parents of children between the ages of 12 - 180 months who came for routine paediatric care at the out...

OBJECTIVE To evaluate the response of the vaginal mucosa with TX-004HR and its correlation with vulvar and vaginal atrophy (VVA) symptoms, and whether visual examination is a useful measure for assessing VVA. METHODS REJOICE was a 12-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study of a vaginal, muco-adhesive, 17β-estradiol softgel capsule (TX-004HR 4, 10, and 25...

Background: Vulvovaginal atrophy is an inflammatory condition linked with estrogenic deficiency, as well as decreased lubrication. The study aimed at the objective measurements of vaginal moisture (RH%), in fertile women and in postmenopausal women before and during treatment with a non-estrogenic moisturizing gel. Methods: The study followed a stepwise design. Acute: 5 women with postmenopausa...

OBJECTIVE To determine whether hot flashes, depressed mood, sleep, cognitive and sexual symptoms correlate with urinary follicle-stimulating hormone (FSH), estrone (E(1)G), and testosterone (T) and with each other during the menopausal transition and early postmenopause (PM). METHODS Forty-one women who transitioned from middle or late transition stage to PM rated symptoms and provided monthl...

INTRODUCTION Many postmenopausal women who are on hormone replacement therapy discontinue medications due to vaginal bleeding. Tibolone, a synthetic steroid, has minimal stimulatory effect on the endometrium. The aim of this study was to assess the effects of continuous HRT regimen and tibolone on the onset of vaginal bleeding and vaginal maturation value. MATERIALS AND METHODS A total of 150...

INTRODUCTION Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist approved by the U.S. Federal Drug Administration for the treatment of "moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause." Although published, peer-reviewed, placebo-controlled studies have shown objective improvement in dyspareunia and in vaginal atrop...